ADC源起:始于差异、终于不同
来源:2022 ASCO(LBA3
by Shanu Modi[1])
ADC未来:走向何方?
1913年,著名的德国化学家保罗·埃利希(Paul Ehrlich)提出了“魔法子弹”概念[6],被认为是ADC药物的最早描述。2000年,FDA批准首个ADC药物Mylotarg上市,本以为ADC药物春天来临,却因为疗效不显著和脱靶毒性而退市,令ADC再次坠入黑暗之渊。
各类有效载荷近似细胞毒性范围[9]
- 上下滑动查看参考资料 -
[2] Trastuzumab
Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med . 2022
Mar 24;386(12):1143-1154.
[3] Daiichisankyo R&D Day
2022, https://www.daiichisankyo.com/-investors/library/materials/
[4]https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-destiny-pantumor02-shows-positive-results.html
[5] https://www.daiichisankyo.com/files/news/pressrelease/pdf/202303/20230320_E.pdf
[6] Antibody-drug
conjugates: current status and future directions. Drug Discov Today. 2014
Jul;19(7):869-81
[7] ONCOLOGY
REPORTS 19: 1493-1498, 2008;MABS 2019, VOL. 11, NO. 6, 987–995
[8] Lung
Cancer: Targets and Therapy 2021:12 103–114
[9] Chem. Pharm. Bull. 67, 173–185 (2019);David M. Goldenberg & Robert M. Sharkey (2019) Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan, mAbs 11:6, 987-995;Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate,[fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67:173–85
Copyright © 2023 PHARMCUBE. All Rights Reserved.
欢迎转发分享及合理引用,引用时请在显要位置标明文章来源;如需转载,请给微信公众号后台留言或发送消息,并注明公众号名称及ID。
免责申明:本微信文章中的信息仅供一般参考之用,不可直接作为决策内容,医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。
医药魔方读者调研问卷
感谢陪伴 期待反馈
扫描二维码 提供宝贵建议